ALBUQUERQUE, N.M.--(BUSINESS WIRE)--TruTouch Technologies, a pioneer in non-invasive intoxication measurement systems, today named longtime industry executive Dr. Richard D. Gill as President and Chief Executive Officer.
Dr. Gill joins TruTouch after nearly 30 years of strategic management, research and technology commercialization experience. Prior to joining TruTouch, Dr. Gill was CEO of ProNAi, Inc., a nucleic acid-based therapeutic development company, where he helped raise nearly $12 million in venture funding. Dr. Gill also has served as President and CEO of Signet Laboratories, Inc., a maker of monoclonal antibodies, until its acquisition by Covance.
“I am delighted to join the TruTouch team, as the company enters an exciting period for its technology and its applications in non-invasive detection of intoxication,” said Dr. Gill. “As recently announced, TruTouch has been awarded federal funding to further develop its flagship platform, which has been placed at various law enforcement and transportation-based organizations in the past few years. We are looking forward to continuing our funding drive to create the next generation of devices in development, as well as to broaden the technology's promising future markets and applications.”
Prior to Signet, Dr. Gill was President and CEO of AnVil, Inc. His earlier career highlights include serving as General Manager and Senior Vice President of BTG International, where he led the global biosciences sector. In that role Dr. Gill helped lead the management buyout of British Technology Group plc from the British government, the firm’s expansion into international markets, and its subsequent initial public offering. Richard began his career at Unilever.
Dr. Gill currently serves on the board of Launchpad Venture Group, Neuroptix, NABsys, ERA Biotech, and SynDevRx. He holds a Ph.D. in Endocrinology and a B.Sc. with honors in Physiology and Biochemistry from Reading University, UK.
About TruTouch Technologies
TruTouch Technologies, Inc. develops, manufactures and sells patented non-invasive alcohol testing systems into both existing and emerging alcohol testing markets. Inspired by the potential to place its passive, durable systems virtually anywhere, TruTouch's vision is to create a world where intoxication is routinely intercepted before it does harm.
Contact:
TruTouch Technologies, Inc. Dr. Richard D. Gill, President/CEO, 269-823-8430 Richard.Gill@TruTouchTechnologies.com Patricia Eads, Controller, 505-272-7050 Pat.Eads@TruTouchTechnologies.com
